SAIMSARA Journal

Machine Generated Science • ISSN 3054-3991

Statin: Scoping Review with ☸️SAIMSARA.

Cardiac & Vascular Health icon

Cardiac & Vascular Health

Issue 1, Volume 1, 2026

DOI: 10.62487/f5760313

Editorial note
• Last update: 2026-03-27 12:21:06
What is this paper about
This paper shows that statins remain one of the strongest cardiovascular therapies, consistently linked to fewer major events and lower mortality across very large populations, but not without trade-offs such as diabetes risk, muscle symptoms, and rises in lipoprotein(a). The full paper is worth reading because it shows where the benefit is most convincing, where the risks matter most, and how to think more clearly about the real balance between protection and harm.


Abstract: This paper aims to comprehensively synthesize the current evidence on the multifaceted effects of statin therapy, encompassing both its benefits and risks across various physiological systems and patient populations, to identify key clinical implications and future research directions. The review utilises 4734 original studies with 141,699,669 total participants (topic deduplicated ΣN). Across this evidence map, statin therapy most consistently aligns with improved cardiovascular outcomes in high-risk settings, including signals supporting reduced major adverse cardiovascular events and mortality, while also highlighting recurrent safety trade-offs such as higher risk of incident type 2 diabetes and increases in lipoprotein(a). Beyond lipid lowering, the mapped literature repeatedly points to pleiotropic pathways—anti-inflammatory and plaque-stabilizing effects—appearing across domains such as heart failure, stroke, and infectious/critical illness outcomes. At the same time, associations with musculoskeletal symptoms and other system-specific adverse outcomes underscore the need for individualized risk–benefit discussions and monitoring, particularly in susceptible subgroups. Interpretation is limited by the scoping design and the LLM-assisted classification workflow, which prioritize breadth over causal certainty and may introduce misclassification. Clinically, the map supports early and sustained statin use where cardiovascular risk is high while motivating research to better stratify diabetes risk and to clarify the clinical significance of statin-associated lipoprotein(a) increases.

Keywords: Statins; Type 2 diabetes mellitus; Atrial fibrillation; Heart failure; Dementia; Chronic kidney disease; Adverse drug reactions; Lipoprotein; Acute myocardial infarction; Sepsis-associated acute kidney injury

Review Stats

Get access to the full paper

Unlock the full evidence map

The full evidence review, including the Introduction, Methods, Results, Discussion, Conclusion, figures, and complete reference index, opens after purchase or sign-in. The Evidence Object JSON is a separate machine-readable evidence product: a concentrated synthesis of results, topic-level evidence, and discussion across original and non-original studies. It can be directly input into your LLM, agent, or RAG workflow.

Reference Index (369)